Key Takeaways:
Genentech Inc. secured the first U.S. Food and Drug Administration approval for a cancer therapy guided by circulating tumor DNA, a milestone in personalized medicine that reduced patient deaths by 41% in a pivotal trial.
"Combining our cancer immunotherapy Tecentriq with state-of-the-art MRD testing allows more precise identification of patients who are candidates for intervention and those who might safely avoid unnecessary treatment," Levi Garraway, chief medical officer at Genentech, a member of the Roche Group, said in a statement.
The FDA approved Tecentriq, or atezolizumab, for adult patients with muscle-invasive bladder cancer (MIBC) who show molecular residual disease (MRD) via Natera Inc.’s Signatera test after bladder removal surgery. The approval was based on the Phase III IMvigor011 study, which showed Tecentriq reduced the risk of disease recurrence or death by 36% and the risk of death alone by 41% in patients with detectable ctDNA.
This new approach marks a significant shift from the traditional "watch and wait" period following surgery for MIBC, a time of uncertainty for many patients. Nearly half of the 150,000 people diagnosed with the aggressive disease globally each year see their cancer return after surgery. The Signatera test can detect microscopic traces of cancer in the blood before they are visible on standard scans, allowing for earlier, targeted intervention.
The IMvigor011 trial enrolled 250 patients who tested positive for ctDNA after cystectomy. The results demonstrated that the ctDNA-guided approach could effectively select patients who would benefit most from adjuvant immunotherapy.
"Historically, we relied on imaging to tell us when cancer had returned, but that also meant millions of cancer cells were already present," said Thomas Powles, the lead investigator for IMvigor011 and Chair of Barts Cancer Centre. "Signatera detected tumor DNA at an earlier timepoint and provided us with a significant head start to improve outcomes."
The FDA simultaneously approved the Signatera CDx test as a companion diagnostic for Tecentriq. This is the first such approval for a blood-based MRD test, solidifying its role in the emerging field of personalized oncology. For patients who remained MRD-negative after surgery, the trial data showed a 97% two-year overall survival rate with no additional treatment.
Tecentriq is a monoclonal antibody that works by blocking the PD-L1 protein, which helps cancer cells hide from the immune system. By inhibiting PD-L1, the drug may enable the re-activation of T-cells to fight the cancer.
The approval strengthens Roche's oncology portfolio and establishes Natera's Signatera test as a key diagnostic tool in bladder cancer. This ctDNA-guided approach is now being investigated in other cancer types, potentially opening up significant new markets for both companies. Investors will be watching for adoption rates by oncologists and further data on the long-term impact on patient survival.
This article is for informational purposes only and does not constitute investment advice.
